Mobia Medical went public but saw its shares drop over 20% on the first day, reflecting investor caution. The company’s Vivistim Paired VNS system targets the stroke recovery market, with revenues expected to double to $32 million by 2025. However, operating losses are also projected to nearly double, raising concerns about profitability. Despite a strong cash position and sales growth, high costs and lack of operating leverage keep investors hesitant, with some waiting for clearer signs of sustained commercial success before investing.
The Farm Progress Show 2026, held in Boone, Iowa from Sept. 1-3, introduces three major innovations: an expanded Agronomy Zone with research-grade crop plots and expert tours, new $60 premium ticket packages including admission, a hat, and lunch vouc...
Ormat Technologies introduced the Ormega100, the industry's largest binary power generation unit delivering 100 MW output, designed to accelerate commercialization and scaling of Enhanced Geothermal Systems (EGS). With 60 years of expertise and exten...
ADARx Pharmaceuticals announced it will present Phase 1/2 clinical data for Onvuzosiran, an RNA therapy for hereditary angioedema (HAE), at the 2026 EAACI Congress in Istanbul. Onvuzosiran targets plasma prekallikrein to prevent swelling attacks by r...
FDH Aero, a leading aerospace and defense supply chain provider, has agreed to a majority investment from Bain Capital Private Equity, with Audax Private Equity remaining a significant investor. This partnership aims to accelerate FDH's growth strate...
Cyabra, an AI-driven disinformation intelligence company, has secured a contract worth over $500,000 to provide its technology to a leading international research institute focused on tracking global hate speech. The platform will help identify coord...
